Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06086613 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers
A Phase 1 study, sponsored by Angitia Incorporated Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
NCT06086613 is a Phase 1 study that has completed, run by Angitia Incorporated Limited. The registered enrollment target is 72 participants.
The verdict
NCT06086613, a Phase 1 study, has completed, sponsored by Angitia Incorporated Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
Study Summary
To understand if AGA2115 is safe and well tolerated in healthy adult volunteers.
Interventions
- DRUG Placebo
- DRUG AGA2115
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-10-03 |
| Est. Completion | 2024-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06086613
The ClinicalTrials.gov registry entry for NCT06086613 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Angitia Incorporated Limited, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06086613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06086613 about?
NCT06086613 is a clinical study titled "A First-in-Human Study Evaluating AGA2115 in Adult Healthy Volunteers". To understand if AGA2115 is safe and well tolerated in healthy adult volunteers.
What is the current status of trial NCT06086613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2023-10-03. Estimated completion is 2024-10-17.
What interventions are being tested in trial NCT06086613?
The interventions under investigation include: Placebo (DRUG), AGA2115 (DRUG).
Who is sponsoring clinical trial NCT06086613?
This trial is sponsored by Angitia Incorporated Limited, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.